Tamizaje prenatal: análisis de riesgo de aneuploidía

Autores/as

  • Andrés Salamanca

DOI:

https://doi.org/10.18597/rcog.566

Resumen

El tamizaje prenatal de aneuploidías ha tenido una importante evolución desde los tiempos de la utilización de la edad materna como único método de tamizaje, hasta la época actual con el empleo de marcadores ultrasonográficos y serológicos de primer trimestre.

En esta revisión del tema, se hace énfasis en la utilización de la sonolucencia nucal como marcador ultrasonográfico del primer trimestre, la forma correcta de usar e interpretar los resultados, así como su interrelación con marcadores serológicos de primero y segundo trimestres.

Los estudios más relevantes sobre el tema revelan tasas de detección que varían con base en las diferentes estrategias escogidas para el tamizaje prenatal y las distintas tasas de falsos positivos.

Cada día aparecen nuevos marcadores y diferentes estrategias de tamizaje que demandan una evaluación exhaustiva antes de ponerlas en práctica en el ejercicio rutinario.

Biografía del autor/a

Andrés Salamanca

Conceptum - Medicina Materno Fetal.

Referencias bibliográficas

Shuttleworth GE. Mongolian imbecility. Br Med J 1909; 2: 661-5.

Nicolaides KH, Sebire NJ, Snijders RJ. The 11- 14 week scan.The diagnosis of fetal abnormalities. 1ra ed, London, Parthenon Publishing Group; 1999. p. 5.

Nicolaides KH, Sebire NJ, Snijders RJ. The 11- 14 week scan. The diagnosis of fetal abnormalities. 1ra ed, London, Parthenon Publishing Group; 1999. p. 6.

Johnson MP, Johnson A, Holzgreve W, Isada NB, Wapner RJ, Treadwell MC, et al. First trimester simple hygroma: cause and outcome. Am J Obstet Gynecol 1993; 168: 156-61.

Hewitt B. Nuchal translucency in the first trimester. Aust NZ J Obstet Gynecol 1993; 33: 389-91.

Shulman LP, Emerson D, Felker R, Phillips O, Simpson J, Elias S. High frequency of cytogenetic abnormalities with cystic hygroma diagnosed in the first trimester. Obstet Gynecol 1992; 80: 80-2.

Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992; 304: 867-89.

Pandya PP, Kondylios A, Hilbert L, Snijders RJ, Nicolaides KH. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 1995; 5: 15-19.

Szabo J, Gellen J. Nuchal fluid accumulation in trisomy 21 detected by vaginosonography in first trimester. Lancet 1990; 336: 1133.

Wilson RD, Venir N, Faguharson DF. Fetal nuchal fluid physiological or pathological? In pregnancies less than 17 menstrual weeks. Prenat Diagn 1992; 12: 755-63.

Ville Y, Lalondrelle C, Doumerc S, Daffos F, Frydman R, Oury JF, et al. First trimester diagnosis of nuchal anomalies: significance and fetal outcome. Ultrasound Obstet Gynecol 1992; 2: 314-16.

Trauffer ML, Anderson CE, Johnson A, Heeger S, Morgan P, Wapner RJ. The natural history of euploid pregnancies with first trimester cystic hygromas. Am J Obstet Gynecol 1994; 170: 1279-84.

Brambati B, Cislaghi C, Tului L, Alberti E, Amidani M, Colombo U, Zuliani G. First trimester Down's syndrome screening using nuchal translucency: a prospective study in patients undergoing chorionic villus sampling. Ultrasound Obstet Gynecol 1995; 5: 9-14.

Comas C, Martinez JM, Ojuel J, Casals E, Puerto B, Borrel A, et al. First trimester nuchal edema as a marker of aneuploidy. Ultrasound Obstet Gynecol 1995; 5: 26-9.

Szabo J, Gellen J, Szenere G. First trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age. Ultrasound Obstet Gynecol 1995; 5: 161-3.

Nadel A, Bromley B, Benacerraf BR. Nuchal thickening or cystic hygromas in first and early second trimester fetuses: prognosis and outcome. Obstet Gynecol 1993; 82: 43-8.

Savoldelli G, Binkert F, Achermann J, Scmid W. Ultrasound screening for chromosomal anomalies in the first trimester of pregnancy. Prenat Diagn 1993; 13: 513-18.

Schulte-Vallentin M, Schindler H. Non-echogenic nuchal oedema as a marker in trisomy 21 screening. Lancet 1992; 339: 1053.

Van Zalen-Sprock MM, Van Vugt JMG, Van Geijn HP. First trimester diagnosis of cystic hygroma course and outcome. Am J Obstet Gynecol 1992; 167: 94-8.

Cullen MT, Gabrielli S, Green JJ, Rizzo N, Mahoney MJ, Salafia C, et al. Diagnosis and significance of cystic hygroma in the first trimester. Pren Diagn 1990; 10: 643-51.

Suchet IB, Van der Westhuizen NG, Labatte MF. Fetal cystic hygromas: further insights into their natural history. Can Assoc Radiol J 1992; 6: 420-4.

Bower S, Chitty L, Bewley S, Roberts L, Clark T, Fisk NM, Maxwell D, Rodeck CH. First trimester nuchal translucency screening of the general population: data from three centers [abstract]. Presented at the 27th British Congress of Obstetrics and Gynaecology. Dublin: Royal College of Obstetrics and Gynaecology, 1995.

Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJ, et al. The implementation of first trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thicknes in two maternity units. Ultrasound Obstet Gynecol 1995; 5: 20-5.

Bewley S, Roberts LJ, Mackinson M, Rodeck CH. First trimester fetal nuchal translucency: problems with screening the general population. II. Br J Obstet Gynecol 1995; 102: 386-8.

Korman LH, Morssink LP, Beekhuis JR, DeWolf BTHM, Heringa MP, Mantingh A. Nuchal translucency can not be used as screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 1996; 16: 797-805.

Zimmerman R, Hucha A, Salvodelli G, Binkert F, Acherman J, Grudzinskas JG. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Br J Obstet Gynecol 1996; 103: 1009-14.

Taipale P, Hiilesmaa V, Salonen R, Ylostalo P. Increased nuchal translucency as a marker for fetal chromosomal defects. N Engl J Med 1997; 337: 1654-8.

Hafner E, Schuchter K, Liebhart E, Philipp K. Results of routine nuchal fetal translucency measurements at 10-13 weeks in 4233 unselected pregnant women. Prenat Diagn 1998; 18: 29-34.

Pajkrt E, Van Lith JMM, Mol BWJ, Bleker OP, Bilardo CM. Screening for Down's syndrome by fetal nuchal translucency measurements in a general obstetrics population. Ultrasound Obstet Gynecol 1998; 12: 163-9.

Nicolaides KH, Sebire NJ, Snijders RJ. The 11-14 week scan. The diagnosis of fetal abnormalities. 1ra ed, London, Parthenon Publishing Group; 1999. p. 21.

Rodeck CH, Whittle MJ. Fetal medicine. Basic science and clinical practice.1ra ed, London, Churchill Livingstone; 1999. p. 574.

Stewart TL, Malone FD. First trimester screening for aneuploidy: nuchal translucency sonography. Sem in Perinatology 1999; 23(5): 369-381.

Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352: 343-46.

Jaeschke R, Guyatt G, Sackett DL. How to use an article about a diagnostic test. Are the results of the study valid? JAMA 1994; 271: 389-391.

Jaeschke R, Guyatt G, Sackett DL. How to use an article about a diagnostic test. What are the results and will they help me in caring for my patients. JAMA 1994; 271: 703-707.

Whitlow BJ, Economides DL. The optimal gestational age to examine fetal anatomy and measure nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 1998; 11: 258-61.

Braithwaite JM, Economides DL. The measurements of nuchal translucency with transabdominal and transvaginal sonography-success rates, repeatability and level of agreement. Br J Radiol 1995; 68: 720-3.

Braithwaite JM, Morris RW, Economides DL. Nuchal translucency measurements: frequency, distribution and changes with gestation in a general population. Br J Obstet Gynaecol 1996; 103: 1201-4.

Whitlow BJ, Chatzipapas IK, Economides DL. The effect of fetal neck position on nuchal translucency measurement. Br J Obstet Gynaecol 1998; 105: 872-6.

Herman A, Maymon R, Dreazen E, Caspi E, Bukovsky I, Weinraub Z. Nuchal translucency audit: a novel image- scoring method. Ultrasound Obstet Gynecol 1998; 12: 398-403.

Braithwaite JM, Kadir RA, Pepera TA, Morris RW, Thompson PJ, Economides DL. Nuchal translucency measurement: training a potential examiners. Ultrasound Obstet Gynecol 1996; 8: 192-5.

Monni G, Zoppi MA, Ibba RM, Floris M. Results of measurement of nuchal translucency before and after training. Lancet 1997; 350: 1631.

Pandya PP, Altman D, Brizot ML, Pettersen H, Nicolaides KH. Repeatability of measurement of fetal nuchal translucency thickness. Ultrasound Obstet Gynecol 1995; 5: 334-7.

Schuchter K, Wald N, Hackshaw AK, Hafner E, Liebhart E. The distribution of nuchal translucency at 10-13 weeks of pregnancy. Prenat Diagn 1998; 18: 281-6.

Pajkrt E, de Graaf IM, Mol BW, van Lith JM, Bleker OP, Bilardo CM. Weekly nuchal translucency measurements in normal fetuses. Obstet Gynecol 1998; 91: 208-11.

Braithwaite JM, Morris RW, Economides DL. Nuchal translucency measurements: frequency, distribution and changes with gestation in a general population. Br J Obstet Gynaecol 1996; 103: 1201-4.

Pandya PP, Snijders RJ, Johnson SJ, Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 1995; 102: 957-62.

Koulisher L, Gillerot Y. Down's syndrome in Wallonia (South Belgium), 1971-1978: cytogenetics and incidence. Hum Genet 1980; 54: 243-50.

Hook EB, Lindsjo A. Down syndrome in live births by single year maternal age interval in a Swedish study: comparison with results from a New York state study. Am J Hum Genet 1978; 30: 19-27.

Hecht CA, Hook EB. The imprecision in rates of Down syndrome by 1-year maternal age intervals: a critical analysis of rates used in biochemical screening. Prenat Diagn 1994; 14: 729-38.

Snijders RJ, Sebire NJ, Nicolaides KH. Maternal age and gestational age-specific risks for chromosomal defects. Fetal Diag Ther 1995; 10: 356-67.

Nicolaides KH, Sebire NJ, Snijders RJ. The 11-14 week scan. The diagnosis of fetal abnormalities. 1ra ed, London, Parthenon Publishing Group; 1999. p. 11-12.

Acuña JM. Indicaciones de diagnóstico citogenético prenatal. En: Gómez PI, Ruiz AI. Temas de interés en ginecología y obstetricia.1 ra ed. Bogotá. Universidad Nacional de Colombia; 1999. p. 114.

Snijders RJ, Nicolaides KH. Assesment of risk. In: ultrasound markers for fetal chromosomal defects. Carnforth, UK: Parthenon Publishing; 1996. p. 109-13.

Nicolaides KH, Sebire NJ, Snijders RJ. The 11-14 week scan. The diagnosis of fetal abnormalities. 1ra ed, London, Parthenon Publishing Group; 1999. p. 8.

Nicolaides KH, Sebire NJ, Snijders RJ. The 11-14 week scan. The diagnosis of fetal abnormalities. 1ra ed, London, Parthenon Publishing Group; 1999. p. 29-30.

Thilaganathan B, Slack A, Wathen N. Effect of first trimester nuchal translucency on second trimester maternal serum biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 1997; 10: 261-4.

Kadir R, Economides D. The effect of nuchal translucency measurement on second trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 1997; 9: 244-7.

Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard JC, Frydman R. Screening for Down Syndrome using first trimester ultrasound and second trimester maternal serum markers in a low risk population: a prospective longitudinal study. Ultrasound Obstet Gynecol 2001; 18: 26-31.

Schuchter K, Hafner E, Stangl G, Ogris E, Philipp K. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low risk population. Ultrasound Obstet Gynecol 2001; 18: 23-25.

Nicolaides KH, Sebire NJ, Snijders RJ. The 11-14 weeks scan. The diagnosis of fetal abnormalities. 1ra ed, London, Parthenon Publishing Group; 1999. p. 38.

Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimester. Br J Obstet Gynecol 1997; 104: 811-17.

Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free B-human chorionic gonadotropin and pregnancy-associated plasma protein A. Ultrasound Obstet Gynecol 1999; 13: 231-7.

Brizot Ml, Snijders RJ, Butler J, Bersinger NA, Nicolaides KH. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 1995; 102: 127-32.

De Graaf IM, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS, Van Lith JM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 1999; 19: 458-62.

Brizot ML, Snijders RJ, Bersinger NA, Kuhn P, Nicolaides KH. Maternal serum pregnancy associated placental protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 1994; 84: 918-22.

Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. First trimester screening for aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1977; 10: 381-6.

De Biaso P, Siccardi M, Volpe G, Famularo L, Santi P, Canini S. First trimester screening for Down's syndrome using nuchal translucency measurement with free B-hCG and PAPP-A between 10 and 13 weeks of pregnancy: the combined test. Prenat Diagn 1999; 19: 360-3.

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the serum, urine and ultrasound screening study (SURUSS). Health Technology Assessment 2003; Vol 7: No 11.

Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides KH. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001; 358: 1665 -1667.

Otano L, Aiello H, Igarzabal L, Matayoshi T, Gadow EC. Association between first trimester absence of fetal nasal bone on ultrasound on Down's Syndrome. Prenat Diagn 2002; 22: 930-932.

Orlandi F, Bilardo CM, Campogrande M, Krantz D, Hallahan T, Rossi C, et al. Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in Down's syndrome risk assessment. Ultrasound Obstet Gynecol. En prensa, 2003.

Zoppi MA, Ibba RM, Axinan C, Floris M, Manca F, Monni G. Absence of fetal nasal bone and aneuploidies at first trimester nuchal translucency screening in 5425 unselected pregnancies. Prenat Diagn. En prensa, 2003.

Cicero S, Longo D, Rembouskos G, Sachini C, Nicolaides KH. Absent nasal bone at 11-14 weeks of gestation and chromosomal defects. Ultrasound Obstet Gynecol. En prensa, 2003.

Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency and absent fetal nasal bone, free b-HCG and PAPP-A at 11-14 weeks. Prenat Diagn 2003; 23: 306-310.

Nicolaides KH. Screening for chromosomal defects. Ultrasound Obstet Gynecol 2003; 21: 3131-321.

Cómo citar

1.
Salamanca A. Tamizaje prenatal: análisis de riesgo de aneuploidía. Rev. Colomb. Obstet. Ginecol. [Internet]. 30 de diciembre de 2003 [citado 16 de agosto de 2022];54(4):213-26. Disponible en: https://revista.fecolsog.org/index.php/rcog/article/view/566

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

2003-12-30

Número

Sección

Artículo de Revisión